|1.||van Gilst, Wiek H: 6 articles (07/2008 - 11/2004)|
|2.||Asselbergs, Folkert W: 5 articles (07/2008 - 11/2004)|
|3.||Hillege, Hans L: 5 articles (07/2008 - 11/2004)|
|4.||de Jong, Paul E: 4 articles (01/2008 - 03/2005)|
|5.||Fish, Brian L: 3 articles (11/2014 - 01/2012)|
|6.||Moulder, John E: 3 articles (11/2014 - 01/2012)|
|7.||Kessler, Michèle: 3 articles (08/2012 - 10/2002)|
|8.||Zannad, Faiez: 3 articles (08/2012 - 10/2002)|
|9.||Liu, Jian-gang: 3 articles (12/2010 - 05/2010)|
|10.||Zhang, Da-wu: 3 articles (12/2010 - 05/2010)|
|1.||Hypertension (High Blood Pressure)
08/01/2006 - "Two hundred fifty three children ages 6-16 with hypertension or with high normal blood pressure with an associated medical condition requiring antihypertensive therapy were enrolled at 78 clinical sites in the US, Russia, and Israel in a double blind study to evaluate the efficacy of fosinopril compared to placebo. "
12/01/2001 - "Fosinopril treatment with 10-40 mg/day was effective in monotherapy of hypertension in 85% patients and was well tolerated. "
05/01/1996 - "Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension."
01/01/1996 - "The tolerability and antihypertensive efficacy of Fosinopril were assessed in 34 elderly patients with mild to moderate hypertension. "
01/01/1992 - "Fosinopril may provide end-organ protection against the effects of hypertension and antihypertensive therapy; this drug potentially protects the kidney by increasing renal functional reserve, while maintaining cardiac left ventricular performance. "
07/01/1997 - "Comparative studies of 3 or 6 months' duration with fosinopril 10 to 40 mg/day have demonstrated clinical efficacy significantly superior to that of placebo in patients with heart failure [mostly New York Heart Association (NYHA) functional class II or III]. "
07/01/1997 - "Fosinopril treatment consistently increased exercise duration and improved heart failure symptoms in these patients. "
12/01/1995 - "In conclusion, fosinopril, at an initial dose of 10 mg once daily, subsequently titrated as tolerated to 40 mg once daily, increased exercise tolerance and reduced the frequency of clinical events indicative of worsening heart failure."
01/01/2004 - "The purpose of the study was to examine the effect of fosinopril on the magnitude of neurohumoral and proinflammatory activation in patients with severe heart failure (HF). "
07/01/1999 - "The objective of this study was to evaluate the hemodynamic and clinical effects of fosinopril in patients with heart failure. "
07/01/2005 - "Fosinopril is effective in preventing myocardial no-reflow, improving left ventricular function, and reducing infarct area during acute myocardial infarction and reperfusion in mini-swine."
08/01/1998 - "The results of the Fosinopril in Acute Myocardial Infarction Study suggest that early treatment with fosinopril can benefit patients with acute myocardial infarction in addition to a prevention of LV remodeling."
08/01/1998 - "Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. "
10/01/1997 - "The Fosinopril in Acute Myocardial Infarction Study (FAMIS) was a 2-year randomized, double-blind, placebo-controlled multicenter study investigating the hemodynamic and clinical effects of early (< 9 h from onset of symptoms) administration of fosinopril in 285 patients with anterior AMI undergoing thrombolysis within 6 h of symptom onset. "
10/01/1997 - "Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS)."
11/01/1990 - "Reduction of GFR, restoration of response to API and reduction of proteinuria, indicate that ACE inhibition with fosinopril ameliorates HF and GH. "
10/01/2001 - "Proteinuria decreased at the end of the study by a mean of 57% in the fosinopril group and increased by 7% in the group receiving dihydropiridine. "
07/01/2006 - "The result suggested that fosinopril significantly reduced proteinuria and alleviated renal tubular damage, but did not influence blood pressure and components of systemic RAS in normotensive children with SRINS."
01/01/2006 - "After 12 weeks of treatment fosinopril reduced proteinuria by 0.95 g/24 h (95% CI -1.21 to -0.69). "
07/01/2002 - "Administration of monopril in exhausted functional renal reserve permits preventing development of proteinuria or allows a lapse of time for it to develop."
|5.||Type 2 Diabetes Mellitus (MODY)
02/01/1999 - "In conclusion, fosinopril lowered cVCAM-1 levels along with microalbuminuria in NIDDM. "
02/01/1999 - "Fosinopril (10 mg/day) was administered over 12 weeks to 11 microalbuminuric patients with non-insulin-dependent diabetes mellitus (NIDDM). "
12/01/1994 - "Fosinopril appears to have significant cardiac benefits in patients with NIDDM who have normal or mildly elevated BP. These benefits are achieved without adversely affecting renal status and without impairing metabolic control of diabetes."
12/01/1994 - "Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM."
12/01/1994 - "Fifty-five NIDDM subjects with normal BP or mild, untreated hypertension were randomized to treatment with the ACE-inhibitor fosinopril or placebo for 6 months in a randomized, double-blind trial to determine the effect of fosinopril on echocardiographic measurements. "
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Phosphinic Acids (Phosphinic Acid)
|1.||Renal Dialysis (Hemodialysis)
|4.||Transplantation (Transplant Recipients)
|5.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)